Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Athenex Inc (ATNX)

Athenex Inc (ATNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,759
  • Shares Outstanding, K 8,663
  • Annual Sales, $ 102,820 K
  • Annual Income, $ -103,430 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.36
  • Price/Sales 0.02
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -15.58
  • Most Recent Earnings $-3.38 on 03/20/23
  • Next Earnings Date 05/30/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2016 +0.74%
on 05/24/23
1.4699 -86.18%
on 05/03/23
-1.0469 (-83.75%)
since 04/24/23
3-Month
0.2016 +0.74%
on 05/24/23
2.9800 -93.18%
on 03/06/23
-2.5369 (-92.59%)
since 02/24/23
52-Week
0.2016 +0.74%
on 05/24/23
23.8000 -99.15%
on 08/09/22
-9.8069 (-97.97%)
since 05/24/22

Most Recent Stories

More News
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO

/PRNewswire/ -- Quantum Leap Healthcare Collaborative (Quantum Leap) and Athenex, Inc. (Nasdaq: ATNX) will present the findings of the I-SPY 2 TRIAL evaluation...

ATNX : 0.2031 (-23.39%)
First Republic, Athenex fall; Franchise Group, Exelixis rise

Stocks that traded heavily or had substantial price changes Monday: First Republic, Athenex fall; Franchise Group, Exelixis rise

NYCB : 10.55 (-8.26%)
SBNY : 1.2500 (-3.85%)
FL : 23.96 (+3.32%)
EXEL : 34.12 (+2.77%)
FRC : 3.51 (-43.30%)
SPGI : 483.31 (+0.61%)
ATNX : 0.2031 (-23.39%)
Athenex: Q4 Earnings Snapshot

Athenex: Q4 Earnings Snapshot

ATNX : 0.2031 (-23.39%)
Athenex: Q3 Earnings Snapshot

Athenex: Q3 Earnings Snapshot

ATNX : 0.2031 (-23.39%)
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.2031 (-23.39%)
Athenex Provides Second Quarter 2022 Financial Results and Business Update

Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds...

ATNX : 0.2031 (-23.39%)
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...

ATNX : 0.2031 (-23.39%)
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and...

ATNX : 0.2031 (-23.39%)
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will be used...

ATNX : 0.2031 (-23.39%)
Athenex to Participate in Truist Securities Cell Therapy Symposium

BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and...

ATNX : 0.2031 (-23.39%)

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

3rd Resistance Point 0.2951
2nd Resistance Point 0.2761
1st Resistance Point 0.2396
Last Price 0.2031
1st Support Level 0.1841
2nd Support Level 0.1651
3rd Support Level 0.1286

See More

52-Week High 23.8000
Fibonacci 61.8% 14.7854
Fibonacci 50% 12.0008
Fibonacci 38.2% 9.2162
Last Price 0.2031
52-Week Low 0.2016

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar